Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2017

01.02.2017 | Brachytherapie | Literatur kommentiert

Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?

verfasst von: Prof. Dr. Simone Marnitz

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Auszug

Die primäre Radiochemotherapie (RCT) ist die Standardbehandlung für Patientinnen mit nodal positiven und/oder lokal fortgeschrittenen Zervixkarzinomen. Die Therapie besteht aus perkutaner Strahlentherapie (EBRT), simultaner Chemotherapie mit Cisplatin und einer intrazervikalen Brachytherapie (BT). Der Einsatz der hoch standardisierten BT auf MRT-Basis konnte die lokale Kontrolle deutlich verbessern und auch die Toxizität unter definierten Kriterien wesentlich absenken [1]. …
Literatur
1.
Zurück zum Zitat Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77CrossRefPubMed Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77CrossRefPubMed
2.
Zurück zum Zitat Zolciak-Siwinska A, Piotrkowicz N, Jonska-Gmyrek J, Nicke-Psikuta M, Michalski W, Kawczynska M, Bijok M, Bujko K (2013) HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy – a phase III study. Radiother Oncol 109(2):194–199CrossRefPubMed Zolciak-Siwinska A, Piotrkowicz N, Jonska-Gmyrek J, Nicke-Psikuta M, Michalski W, Kawczynska M, Bijok M, Bujko K (2013) HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy – a phase III study. Radiother Oncol 109(2):194–199CrossRefPubMed
3.
Zurück zum Zitat Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Cufer T, Beslija S, Eniu A, Todorovic V et al (2016) Cancer control in Central and Eastern Europe: current situation and recommendations for improvement. Oncologist 21(10):1183–1190CrossRefPubMed Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Cufer T, Beslija S, Eniu A, Todorovic V et al (2016) Cancer control in Central and Eastern Europe: current situation and recommendations for improvement. Oncologist 21(10):1183–1190CrossRefPubMed
4.
Zurück zum Zitat Marnitz S, Kohler C, Rauer A, Schneider A, Budach V, Tsunoda A, Mangler M (2014) Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers. Strahlenther Onkol 190(1):34–40CrossRefPubMed Marnitz S, Kohler C, Rauer A, Schneider A, Budach V, Tsunoda A, Mangler M (2014) Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers. Strahlenther Onkol 190(1):34–40CrossRefPubMed
5.
Zurück zum Zitat Lin JF, Berger JL, Krivak TC, Beriwal S, Chan JK, Sukumvanich P, Monk BJ, Richard SD (2014) Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132(2):416–422CrossRefPubMed Lin JF, Berger JL, Krivak TC, Beriwal S, Chan JK, Sukumvanich P, Monk BJ, Richard SD (2014) Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132(2):416–422CrossRefPubMed
6.
Zurück zum Zitat Showalter TN, Camacho F, Cantrell LA, Anderson RT (2016) Determinants of quality care and mortality for patients with locally advanced cervical cancer in Virginia. Medicine (Baltimore) 95(8):e2913CrossRef Showalter TN, Camacho F, Cantrell LA, Anderson RT (2016) Determinants of quality care and mortality for patients with locally advanced cervical cancer in Virginia. Medicine (Baltimore) 95(8):e2913CrossRef
7.
Zurück zum Zitat Tergas AI, Neugut AI, Chen L, Burke WM, Hershman DL, Wright JD (2016) Radiation duration in women with cervical cancer treated with primary chemoradiation: a population-based analysis. Cancer Invest 34(3):137–147CrossRefPubMed Tergas AI, Neugut AI, Chen L, Burke WM, Hershman DL, Wright JD (2016) Radiation duration in women with cervical cancer treated with primary chemoradiation: a population-based analysis. Cancer Invest 34(3):137–147CrossRefPubMed
8.
Zurück zum Zitat Beck T, Sukumvanich P, Rubatt J, Beriwal S, Zorn K, Richard S, Edwards R, Krivak T (2010) Impact of the National Cancer Institute’s clinical announcement on cervical cancer survival. Gynecol Oncol 116(3):S56 Beck T, Sukumvanich P, Rubatt J, Beriwal S, Zorn K, Richard S, Edwards R, Krivak T (2010) Impact of the National Cancer Institute’s clinical announcement on cervical cancer survival. Gynecol Oncol 116(3):S56
9.
Zurück zum Zitat Kohler C, Mustea A, Marnitz S, Schneider A, Chiantera V, Ulrich U, Scharf JP, Martus P, Vieira MA, Tsunoda A (2015) Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial. Am J Obstet Gynecol 213(4):503.e1–503.e7CrossRef Kohler C, Mustea A, Marnitz S, Schneider A, Chiantera V, Ulrich U, Scharf JP, Martus P, Vieira MA, Tsunoda A (2015) Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial. Am J Obstet Gynecol 213(4):503.e1–503.e7CrossRef
10.
Zurück zum Zitat Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer – a prospective correlation of surgical findings with positron emission Tomography/computed Tomography findings. Cancer 117(9):1928–1934CrossRefPubMed Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer – a prospective correlation of surgical findings with positron emission Tomography/computed Tomography findings. Cancer 117(9):1928–1934CrossRefPubMed
11.
Zurück zum Zitat Hong DG, Park NY, Chong GO, Cho YL, Park IS, Lee YS (2010) Survival benefit of laparoscopic surgical staging-guided radiation therapy in locally advanced cervical cancer. J Gynecol Oncol 21(3):163–168CrossRefPubMedPubMedCentral Hong DG, Park NY, Chong GO, Cho YL, Park IS, Lee YS (2010) Survival benefit of laparoscopic surgical staging-guided radiation therapy in locally advanced cervical cancer. J Gynecol Oncol 21(3):163–168CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Marnitz S, Kohler C, Roth C, Fuller J, Bischoff A, Wendt T, Schneider A, Budach V (2007) Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol 183(9):473–478CrossRefPubMed Marnitz S, Kohler C, Roth C, Fuller J, Bischoff A, Wendt T, Schneider A, Budach V (2007) Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol 183(9):473–478CrossRefPubMed
13.
Zurück zum Zitat Marnitz S, Kohler C, Roth C, Fuller J, Hinkelbein W, Schneider A (2005) Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Gynecol Oncol 99(3):536–544CrossRefPubMed Marnitz S, Kohler C, Roth C, Fuller J, Hinkelbein W, Schneider A (2005) Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Gynecol Oncol 99(3):536–544CrossRefPubMed
14.
Zurück zum Zitat Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H et al (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29(13):1678–1685CrossRefPubMed Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H et al (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29(13):1678–1685CrossRefPubMed
15.
Zurück zum Zitat Kim HS, Kim MK, Kim HJ, Han SS, Kim JW (2012) Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer. Cancer Res Treat 44(2):97–103CrossRefPubMedPubMedCentral Kim HS, Kim MK, Kim HJ, Han SS, Kim JW (2012) Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer. Cancer Res Treat 44(2):97–103CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B (2014) Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev 12:CD010401 Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B (2014) Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev 12:CD010401
17.
Zurück zum Zitat Georg P, Potter R, Georg D, Lang S, Dimopoulos JC, Sturdza AE, Berger D, Kirisits C, Dorr W (2012) Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 82(2):653–657CrossRefPubMed Georg P, Potter R, Georg D, Lang S, Dimopoulos JC, Sturdza AE, Berger D, Kirisits C, Dorr W (2012) Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 82(2):653–657CrossRefPubMed
18.
Zurück zum Zitat Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68(3):217–226CrossRefPubMed Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68(3):217–226CrossRefPubMed
19.
Zurück zum Zitat Moore K (2008) Vesicovaginal fistula formation in patients with stage IVA cervical carcinoma – response. Gynecol Oncol 109(3):429–430CrossRef Moore K (2008) Vesicovaginal fistula formation in patients with stage IVA cervical carcinoma – response. Gynecol Oncol 109(3):429–430CrossRef
20.
Zurück zum Zitat Moore KN, Gold MA, McMeekin DS, Zorn KK (2007) Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol 106(3):498–501CrossRefPubMed Moore KN, Gold MA, McMeekin DS, Zorn KK (2007) Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol 106(3):498–501CrossRefPubMed
Metadaten
Titel
Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?
verfasst von
Prof. Dr. Simone Marnitz
Publikationsdatum
01.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1097-x

Weitere Artikel der Ausgabe 3/2017

Strahlentherapie und Onkologie 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.